The US Food and Drug Administration (FDA) has approved labeling changes to Bristol-Myers Squibb's Reyataz (atazanavir), an antiretroviral medication.
The label will now include warnings about kidney and gall stones in addition to updated information regarding drug interaction.
Interstitial nephritis, where in the spaces between the kidney tubules get inflamed, is added to the adverse reactions category of the updated label.
As a part of additional drug interactions, boosted Reyataz (atazanavir/ritonavir) is not recommended with Victrelis (boceprevir), a hepatitis C antiviral agent, and Tegretol and Reyataz without ritonavir is not recommended.
If ritonavir is not used as a booster to counteract a lowering of Reyataz levels, Dilantin (phenytoin) or the barbiturate/anticonvulsant phenobarbital are not recommended in blend with Reyataz.
Reyataz when taken with ritonavir might alter Lamictal levels. Antifungal medication Vfend (voriconazole) may affect Reyataz levels.
